Media Resources

2014

Working Paper 4 – Competition Policy

Policy Brief 3 – Regulation of Mark-ups in the Pharmaceutical Supply Chain

Policy Brief 5 – Sales Taxes on Medicines

Policy Brief 2 – The Role of Health Insurance in the Cost-effective Use of Medicines

Working Paper 1 – External Reference Pricing

Policy Brief 4 – Competition Policy

Policy Brief 1 – External Reference Pricing

Working Paper 2 – The Role of Health Insurance in the Cost-Effective Use of Medicines

Working Paper 3: The Regulation of Mark-ups in the Pharmaceutical Supply Chain

Understanding and Responding To Medicines Promotion

2013

Transparency of Clinical Trial Data on Medicines in the EU

LAC-Global Alliance Statement on Trans-Pacific Partnership and Access to Affordable Medicines

NGOs Condemn the EU Press Release on TRIPS Extension for Least Developed Countries

Comprendre la promotion pharmaceutique et y répondre: Un manuel pratique

EU-India free trade deal puts millions of lives at risk

2012 Annual Report

2012 Financial Statements

2012

ACTA is dead, long live ACTA? ACTA-like measures still in EU IP policies

Time for the final push: Say “No” to ACTA – again

EU Parliament Says No and No Again to EMA: Independent Groups Echo Decision

Big Pharma Spends Over €40 Million per Year Lobbying in the EU, Dwarfing Public Health NGOs

Civil Society Calls on Members of the European Parliament to Condemn ACTA

Divide and Conquer: A look behind the scenes of the EU pharmaceutical industry lobby

Business Conduct Guidelines

Complaints Procedure (EN)

Unlocking the Mysteries of Access to Clinical Trials Data in the EU

2011

Statement on Medicines Patent Pool

Universal Access to Medicines for Non-Communicable Diseases

Drop in Pay-for-Delay Good for Access to Medicines in Europe

Statement on Conflicts of Interests delivered at WHA